Magle Chemoswed Holding Reports Financial Results For Third Quarter 2025
14 november, 08:30
Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.
Q3 2025 KEY INDICATORS
- Net Sales amounted to 71.5 MSEK (64.6)
- EBITDA equaled 33.4 MSEK (26.5)
- Operating profit (EBIT) is 20.3 MSEK (13.8)
- Earnings per share SEK 0.15 (0.89) per share
“The third quarter delivered a stabilised and more aligned performance across the Group, following a challenging Q2. We saw a strong performance from Magle Chemoswed, supported by operational flexibility and sustained demand from Magle Biopolymers. Magle Pharmacept also made solid strategic strides, including international expansion for SmartPAN® and EmboCept® S. While Magle Biopharma continues to face market-driven headwinds, our internal cell therapy development remains a longer-term focus. We are progressing well with our integration and restructuring agenda and remain focused on completing systems alignment and unlocking synergies.” – Justin Pierce, CEO
Contacts Justin & Aaron
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.comand www.maglepharmacept.comand www.maglebiopolymers.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-14 08:30 CET.
Attachments
Ämnen i artikeln
Magle Chemoswed Holding Reports Financial Results For Third Quarter 2025
14 november, 08:30
Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.
Q3 2025 KEY INDICATORS
- Net Sales amounted to 71.5 MSEK (64.6)
- EBITDA equaled 33.4 MSEK (26.5)
- Operating profit (EBIT) is 20.3 MSEK (13.8)
- Earnings per share SEK 0.15 (0.89) per share
“The third quarter delivered a stabilised and more aligned performance across the Group, following a challenging Q2. We saw a strong performance from Magle Chemoswed, supported by operational flexibility and sustained demand from Magle Biopolymers. Magle Pharmacept also made solid strategic strides, including international expansion for SmartPAN® and EmboCept® S. While Magle Biopharma continues to face market-driven headwinds, our internal cell therapy development remains a longer-term focus. We are progressing well with our integration and restructuring agenda and remain focused on completing systems alignment and unlocking synergies.” – Justin Pierce, CEO
Contacts Justin & Aaron
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.comand www.maglepharmacept.comand www.maglebiopolymers.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-14 08:30 CET.
Attachments
Ämnen i artikeln
Fonder
Utredningen mot Intellego
Aktierekar
Försvarsaktier
Fonder
Utredningen mot Intellego
Mest läst
Aktierekar
Försvarsaktier
Senaste nytt
Boliden
Igår, 17:41
Nibe vinnare när uppgångssvit förlängdes
Ukraina
Igår, 17:22
Zelenskyj avfärdar ryska anklagelser
Marknadsöversikt
OMX Stockholm 30
1 DAG %
0,51%
Senast
2 863,64
1 mån
Loading market data...
